This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594–7603.
Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A . Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008; 83: 611–613.
Tefferi A, Stone RM . Iron chelation therapy in myelodysplastic syndrome—Cui bono? Leukemia 2009; 23: 1373.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1998; 91: 1100.
Fletcher RH, Fletcher SW . Prognosis. Clinical Epidemiology: The Essentials 2005. 4th edn. Lippincott Williams and Wilkins: Philadelphia, PA, p 116.
Feinstein AR . Stratifications, Matching and ‘Adjustments’. Principles of Medical Statistics 2002. Chapman Hall/CRC: Boca Ratón, FL, p 556.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jerez, A., Fernández, A., Osma, M. et al. Measuring the prognostic impact of ferritin levels in myelodysplastic syndrome patients: the role of susceptibility biases. Leukemia 24, 640–642 (2010). https://doi.org/10.1038/leu.2009.229
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2009.229